Dr. Fariba Ghodsian

 

Public Presentations

 

  • Women in Enterpreneureship, Anderson Graduate School of Management, UCLA, Los Angeles, CA. June 1992.

  • “Creative Financing of Biotechnology Companies”, Jeffer, Mangels, Butler & Marmaro, Los Angeles, CA, March 1995.

  • Biomedical Industry in LA County – An Insider’s Point of View. In “Government, industry, relationship in LA”, UCLA, Los Angles, CA, May 1995.

  • Women In Bioscience – Financing Workshop. Association for Women in Science(AWIS), University of California in San Diego, CA, May 1995.

  • Business Channel, KWHY, Channel 22. Frequent guest speaker on a live interactive television programs of Market Talk and FM Capital Show. Los Angeles, CA, 1995-1996.

  • PBS, Nightly Business Report, speaker on a special television program on biotechnology, Nationwide, April 1996.

  • Financial Viability of Biotech Industry in LA. In “ICN roundtable on industry, university and government alliances”, UCLA, Los Angeles, CA, April 1996.

  • Public Markets for Biotech from an Analyst’s Perspective. In “Going public: Are you ready?” Connect, San Diego, CA, June 1996.

  • Eighth Annual Health Care Research Forum, Lehman Brothers. Boston, New York, San Francisco & Los Angeles, September-October, 1996.

  • Women in Finance, Investment Finance Club & Women’s Business Connection. Anderson Graduate School of Management, UCLA , Los Angeles, CA, November 1998.

  • Biotechnology: From Dream to Reality. American Technion Society. National Board of Directors Meeting, Los Angeles, CA, March 1999.

  • Women in Healthcare. California State University, Los Angeles, CA, October 1999.

  • Biotechnology: Transition from “Taking” to “Giving”. BioCom’s Analyst Panel (along with biotechnology analysts from Merrill Lynch and Vector Securities), San Diego, CA, October 1999.

  • Tool Companies, Blessed or Doomed? Connect’s Corporate Partnership Forum, San Diego, CA, November 1999.

  • Biotechnology: How Sustainable is the Current Bull Market? 12th Annual Growth Stock Conference, Roth Capital Partners, Laguna Nigel, CA, February 2000.

  • Could 2000 be the Year for Biotechnology? CBS Market watch, Laguna Nigel, CA, February 2000.

  • Trends and Opportunities for Investment in the Healthcare Industry, @pex Capital Partners’ opening ceremony, Seoul, South Korea, February 2000.

  • Trends and Opportunities for Investment in the Healthcare Industry, California Venture Forum, 12th Semi-Annual Investment Conference, Orange, CA, May 2000.

  • Drug Discovery “Tool” Companies: The View of Wall Street, Small Talk 2000, Microfluidics and Microarrays Conference, San Diego, CA, July 2000.

  • Radio WallStreet, regular speaker on a national radio program on biotechnology. January 2000 – present.

  • Financing Climate in the Medical Industry, California Israel Bio-Partnering & Investment Conference, UCLA, Los Angeles, CA, September 2000.

  • Biotechnology: From Science to Business. Technion’s 75th Anniversary, Engineering the Human Body, American Technion Society, Los Angeles, CA, September 2000.

  • Exit Strategies: Acquisition or IPO?, BioFinancing 2000, Turning trends into opportunities, Strategic Research Institute, Dana Point, CA, September 2000.

  • Proteomics: A New Approach to Traditional Drug Discovery, Investing in and commercializing new technologies for Proteomics, Analyst panel (along with biotechnology analysts from SG Cowen, Prudential Vector and William Blair), San Francisco, CA, September 2000.

  • Consolidation in the Drug Industry, International Society of Pharmaceutical Engineers, San Diego, CA, October 2000.

  • Global Partnering in the Drug Industry, Global Partnering 2000, Fullerton, CA, November, 2000.

  • Financing and Trends in the Biotechnology Industry, California Venture Forum, Fullerton, California, November 2000.

  • Cancer Therapeutics, BioTalk Radio Program, Informed Investors, December 2000.

  • Financing Trends in the Biotechnology Industry, Investment & Strategic Partnering Opportunities Conference, moderator of the IPO Panel workshop (along with representatives from Castle Creek Fund, Miravant and Roth Capital), Southern California Biomedical Council, UCLA, February 2001.

  • Financing & Trends in the Biotechnology Industry, 13th Annual Growth Stock Conference, Roth Capital, Laguna Niguel, CA, February 2001.

  • Proteomics: A New Approach to Traditional Drug Discovery, Investing in and commercializing new technologies for Proteomics. Analyst panel (along with biotechnology analysts from SG Cowen, Prudential Vector and William Blair), Boston, MA, February 2001.

  • Exit Strategy: IPO or M&A?, BioFinancing 2001, Turning Trends into Opportunities (Panel presentation along with investment banker from Bear Stern). Iselin New Jersey, March 2001.

  • Transition of Biotechnology from “Taking” to “Giving”, Informed Investors, San Diego, CA, March 2001.

  • Biotechnology Investment: Financing the Genomic Revolution, University of Southern California, April 2001.

  • Biotechnology: Poised for Growth, Informed Investor Healthcare Forum, August 2001.

  • Tool Companies; The Broad Impact on Biotechnology, smallTalk 2001, Microfluidics, Microarray and BioMEMS conference (Keynote speaker along with Stephen Fodor, CEO of Affymetrix), San Diego, CA, August 2001.

  • Bioscience Mergers & Acquisitions: The Effect on Los Angeles, Southern California Biomedical Council’s Networking Forum (Panel presentation along with Alfred Mann, CEO of Minimed and Michael Ziering, CEO of Diagnostic Products Corporation), Los Angeles, CA, August 2001.

  • Transition of Biotechnology from “Taking” to “Giving”, Management Foundations – Class of 2003 Orientation, Anderson Graduate School of Management at UCLA, September 2001.

  • The State of the Industry Round-Table: Analyst Speak Their Peace on Biotech, Strategic Research Institute’s 2nd Annual BioFinancing – Turning the Focus Towards Access to Capital (Panel discussion along with biotechnology analysts from Morgan Stanley, Lehman Brothers, CSFB and Orbimed), San Diego, CA, November 2001.

  • Wall Street’s Perspective: Assessing the Industry Impact of Oncology Licensing and Strategic Partnering, Institute for International Research’s Conference on Building a Balanced Cancer Portfolio, San Diego, CA, December 2001.

  • KNX, Speaker on a special radio program on Biotechnology, December 2001.

  • Bloomberg Television, speaker on a special television program on biotechnology, Nationwide, December 2001.

  • Introduction to the industry and impacts of Pharmaceutical engineering, 14th Annual CSU Biotechnology Symposium “The impact of Biotechnology on the Future of Medicine”, Pomona, CA, January 2002.

  • Healthcare - 2002 Outlook, 14th Annual Roth Capital Partners Growth Stock Conference, Laguna Niguel, CA, February 2002.

  • Featured Presentation by a Company Planning to go Public and Critique by a Panel of Investors, panel discussion along with venture capitalists from Versant, and Guidant at Southern California Biomedical Council’s 4th Annual Conference on Investment & Strategic partnering Opportunities, Los Angeles, CA, March 2002.

  • The Alchemy of BioScience Company Valuation, Moderator of a panel of Venture Capitalists and fund managers from Spray, Sprout, Essex Woodland and Castle-Creek Life Science at Southern California Biomedical Council’s 4th Annual Conference on Investment & Strategic partnering Opportunities, Los Angeles, CA, March 2002.

  • Nanotechnology: Impact on Biotechnology & Medicine, at Strategic Research Institute’s NanoFinancing 2002 – An Investment Framework: Hype, Hope & Homeruns (Panel discussion along with venture capitalist from Lux Capital), San Diego, CA, March 2002.

  • New Technologies, Biotechnology: Will we see some Profits?, at The Anderson School at UCLA’s Conference on The Business of Technology: Perspective, Problems, Profitability, Los Angeles, CA, April 2002.

  • Biotechnology: An Investment Framework, Presentation to Anderson’s Investment Club, Los Angeles, CA, April 2002.

  • Wall Street’s View on Biotech Companies that Commercialize Antibodies, Keynote speaker, Strategic Research Institute’s Conference on Trends in Antibody Deal-Making & Financing, San Diego, CA, April 2002.

  • Biotechnology Industry, CNBC, July 10, 2002

  • Biotechnology: Are we at the bottom? CCG Biotechnology Investment Conference 2002, Beverly Hills, CA, July 2002.

  • Biotechnology: Industry Overview and the state of Funding, In “Frontiers of Biotechnology”, Anderson Graduate School of Management, UCLA, Los Angeles, CA, October 2002.

  • Biotechnology: Are we at the bottom? Strategic Research Institute’s 3rd Annual Business of Biotech Symposium, Scottsdale, AZ, October 2002.

  • Biotechnology: Are we at the Bottom? Lunch Speaker, Ventana Capital Management’s 19th Annual Meeting, Newport Beach, CA, November 2002.

  • Biotechnology: Industry Overview and the state of Funding, In “Frontiers of Biotechnology”, Anderson Graduate School of Management, UCLA, Los Angeles, CA, January 2003.

  • What Wall Street Wants: How to Make the Long and Winding Road Lead to a Pot of Gold? Panel discussion along with venture capitalists and investment bankers from Forward Ventures and Pacific Growth Equities, CalBiosummit 2003, San Diego, CA, March 2003.

  • Looking Forward-A Buyside View of the Biotech Industry in 2010, Panel discussion along with portfolio managers from RCM Capital Management and Stone Pine Capital, BioCom Investor Conference, San Diego, CA, October 2009.

  • Investment, Biotechnology and Careers: Invited guest speaker to the MBA class at Pepperdine University, Malibu, CA, March 2011.

  • The Regenerative Medicine Investment Hypothesis: What is it and how does it differ based on the type of Investor?, Panel discussion along with executives from Dawson James Securities, Baxter Healthcare, Sangamo BioSciences, WBB securities and POSCO Global Strategic Fund, The Stem Cell Meeting on the Mesa, La Jolla, CA, October 2012.

  • The Gene Therapy Financing Window, Panel discussion, The Stem Cell Meeting on the Mesa, La Jolla, CA, October 2015.

 

 

 

 

Back to Dr. Ghodsian's Biography